|Credit: Celgene Corporation|
The drug thalidomide, sold as Thalomid (shown above) by the Celgene Corp.
The drug, sold as Thalomid by Celgene Corp. of Warren, N.Y., was approved in 1998 to treat complications of leprosy. Analogs and derivatives of thalidomide that temper the famed and feared teratogenic effect are in the pipeline too. "We are developing new compounds to harness the beneficial aspects of this drug, while minimizing the negative attributes, to offer patients new therapies in fatal and...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?